Literature DB >> 22884899

Activating killer-cell immunoglobulin-like receptors (KIR) and their cognate HLA ligands are significantly increased in autism.

Anthony R Torres1, Jonna B Westover, Cole Gibbons, Randall C Johnson, David C Ward.   

Abstract

Killer-cell immunoglobulin-like receptor (KIR) proteins are expressed on natural killer (NK) cells and appear important in innate and adaptive immunity. There are about 14 KIR genes on chromosome 19q13.4, composed of those that inhibit and those that activate NK cell killing. Haplotypes have different combinations of these genes meaning that not all genes are present in a subject. There are two main classes of cognate human leukocyte antigen (HLA) ligands (HLA-Bw4 and HLA-C1/C2) that bind to the inhibitory/activating receptors. As a general rule, the inhibitory state is maintained except when virally infected or tumor cells are encountered; however, both increased activation and inhibition states have been associated with susceptibility and protection against numerous disease states including cancer, arthritis, and psoriasis. Utilizing DNA from 158 Caucasian subjects with autism and 176 KIR control subjects we show for the first time a highly significant increase in four activating KIR genes (2DS5, 3DS1, 2DS1 and 2DS4) as measured by chi square values and odds ratios. In addition, our data suggests a highly significant increase in the activating KIR gene 2DS1 and its cognate HLA-C2 ligand (2DS1+C2; p = 0.00003 [Odds ratio = 2.87]). This information ties together two major immune gene complexes, the human leukocyte complex and the leukocyte receptor complex, and may partially explain immune abnormalities observed in many subjects with autism.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884899      PMCID: PMC3469320          DOI: 10.1016/j.bbi.2012.07.014

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  42 in total

1.  Comprehensive human genome amplification using multiple displacement amplification.

Authors:  Frank B Dean; Seiyu Hosono; Linhua Fang; Xiaohong Wu; A Fawad Faruqi; Patricia Bray-Ward; Zhenyu Sun; Qiuling Zong; Yuefen Du; Jing Du; Mark Driscoll; Wanmin Song; Stephen F Kingsmore; Michael Egholm; Roger S Lasken
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

2.  Report from the killer immunoglobulin-like receptor (KIR) anthropology component of the 15th International Histocompatibility Workshop: worldwide variation in the KIR loci and further evidence for the co-evolution of KIR and HLA.

Authors:  J A Hollenbach; A Meenagh; C Sleator; C Alaez; M Bengoche; A Canossi; G Contreras; L Creary; I Evseeva; C Gorodezky; R-A Hardie; T Hemming Karlsen; B Lie; M Luo; M Martinetti; C Navarette; D C M de Oliveira; G Ozzella; A Pasi; E Pavlova; S Pinto; L C Porto; P Santos; A Slavcev; D Srinak; S Tavoularis; S Tonks; E Trachtenberg; S Vejbaesya; D Middleton
Journal:  Tissue Antigens       Date:  2010-03-14

3.  Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism.

Authors:  R I Furlano; A Anthony; R Day; A Brown; L McGarvey; M A Thomson; S E Davies; M Berelowitz; A Forbes; A J Wakefield; J A Walker-Smith; S H Murch
Journal:  J Pediatr       Date:  2001-03       Impact factor: 4.406

4.  The transmission disequilibrium test suggests that HLA-DR4 and DR13 are linked to autism spectrum disorder.

Authors:  Anthony R Torres; Alma Maciulis; E Gene Stubbs; Adele Cutler; Dennis Odell
Journal:  Hum Immunol       Date:  2002-04       Impact factor: 2.850

5.  Altered T cell responses in children with autism.

Authors:  Paul Ashwood; Paula Krakowiak; Irva Hertz-Picciotto; Robin Hansen; Isaac N Pessah; Judy Van de Water
Journal:  Brain Behav Immun       Date:  2010-09-15       Impact factor: 7.217

6.  Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008.

Authors: 
Journal:  MMWR Surveill Summ       Date:  2012-03-30

7.  Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome.

Authors:  Paul Ashwood; Paula Krakowiak; Irva Hertz-Picciotto; Robin Hansen; Isaac Pessah; Judy Van de Water
Journal:  Brain Behav Immun       Date:  2010-08-10       Impact factor: 7.217

8.  Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism.

Authors:  J Croonenberghs; A Wauters; K Devreese; R Verkerk; S Scharpe; E Bosmans; B Egyed; D Deboutte; M Maes
Journal:  Psychol Med       Date:  2002-11       Impact factor: 7.723

9.  Autism spectrum disorders are associated with an elevated autoantibody response to tissue transglutaminase-2.

Authors:  Allen Rosenspire; Wonsuk Yoo; Sherri Menard; Anthony R Torres
Journal:  Autism Res       Date:  2011-04-19       Impact factor: 5.216

10.  Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus.

Authors:  Chul-Woo Pyo; Lisbeth A Guethlein; Quyen Vu; Ruihan Wang; Laurent Abi-Rached; Paul J Norman; Steven G E Marsh; Jeffrey S Miller; Peter Parham; Daniel E Geraghty
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

View more
  18 in total

1.  MHCI requires MEF2 transcription factors to negatively regulate synapse density during development and in disease.

Authors:  Bradford M Elmer; Myka L Estes; Stephanie L Barrow; A Kimberley McAllister
Journal:  J Neurosci       Date:  2013-08-21       Impact factor: 6.167

Review 2.  KIR and HLA under pressure: evidences of coevolution across worldwide populations.

Authors:  Danillo G Augusto; Maria Luiza Petzl-Erler
Journal:  Hum Genet       Date:  2015-06-23       Impact factor: 4.132

Review 3.  Autoimmunity, Autoantibodies, and Autism Spectrum Disorder.

Authors:  Elizabeth Edmiston; Paul Ashwood; Judy Van de Water
Journal:  Biol Psychiatry       Date:  2016-09-01       Impact factor: 13.382

Review 4.  Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment?

Authors:  Dominika Gładysz; Amanda Krzywdzińska; Kamil K Hozyasz
Journal:  Mol Neurobiol       Date:  2018-01-06       Impact factor: 5.590

5.  Brief Report: Low Rates of Herpesvirus Detection in Blood of Individuals with Autism Spectrum Disorder and Controls.

Authors:  Thayne L Sweeten; Lisa A Croen; Gayle C Windham; J Dennis Odell; E Gene Stubbs; Anthony R Torres
Journal:  J Autism Dev Disord       Date:  2019-01

Review 6.  Common Genetic Variants Found in HLA and KIR Immune Genes in Autism Spectrum Disorder.

Authors:  Anthony R Torres; Thayne L Sweeten; Randall C Johnson; Dennis Odell; Jonna B Westover; Patricia Bray-Ward; David C Ward; Christopher J Davies; Aaron J Thomas; Lisa A Croen; Michael Benson
Journal:  Front Neurosci       Date:  2016-10-20       Impact factor: 4.677

7.  A Killer Immunoglobulin - Like Receptor Gene - Content Haplotype and A Cognate Human Leukocyte Antigen Ligand are Associated with Autism.

Authors:  Anthony Torres; Jonna Westover; Michael Benson; Randall Johnson; Annelise Dykes
Journal:  Autism Open Access       Date:  2016-03-28

8.  Genetic polymorphism and evolutionary differentiation of Eastern Chinese Han: a comprehensive and comparative analysis on KIRs.

Authors:  Caiyong Yin; Li Hu; Huijie Huang; Yanfang Yu; Zheng Li; Qiang Ji; Xiaochao Kong; Zhongqun Wang; Jinchuan Yan; Jiangwei Yan; Bofeng Zhu; Feng Chen
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

9.  Redox Regulation and the Autistic Spectrum: Role of Tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the Amygdala.

Authors:  George Anderson; Michael Maes
Journal:  Curr Neuropharmacol       Date:  2014-03       Impact factor: 7.363

10.  Paternal HLA-C and Maternal Killer-Cell Immunoglobulin-Like Receptor Genotypes in the Development of Autism.

Authors:  Moriya Gamliel; Karen L Anderson; Richard P Ebstein; Nurit Yirmiya; David Mankuta
Journal:  Front Pediatr       Date:  2016-07-28       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.